Total EBITDA for 2H2023 beats 2H2022 by 39% to S$18.6 million. FY2023 EBITDA is 5% higher at S$37.0 million vs FY2022.FY2023 Core Healthcare Business Revenue and EBITDA higher at S$$176.2m and S$39.6 million respectively.2nd interim dividend of 0.53 cent per share to be paid on 26 March 2024. Tot…
Total EBITDA for 2H2023 beats 2H2022 by 39% to S$18.6 million. FY2023 EBITDA is 5% higher at S$37.0 million vs FY2022.FY2023 Core Healthcare Business Revenue and EBITDA higher at S$$176.2m and S$39.6 million respectively.2nd interim dividend of 0.53 cent per share to be paid on 26 March 2024. Tot…